Hansa Medical AB establishes a US medical advisory board for IdeS in kidney transplantation

Hansa Medical AB today announced the inception of a US medical advisory board for IdeS in kidney transplantation. The board will assist the company in developing IdeS within transplantation in sensitized patients. 

Hansa Medical AB has previously initiated a similar European advisory board with leading transplantation experts in Europe. The US medical advisory board will be valuable to the further development of IdeS. The two boards are connected through the joint board member, Professor Kathryn Wood, Oxford, UK.

Dr Stanley Jordan
Dr Stanley Jordan, MD, the chairman of the US advisory board.
Dr Stanley Jordan is a Director of Kidney Transplantation and Transplant Immunology, Kidney and Pancreas Transplant Center and Director of Division of Pediatric and Adult Nephrology at Cedars Sinai Medical Center, Los Angeles, USA. Dr Jordan's focus is on immunology and transplantation. He has performed extensive research funded by dozens of research grants and awards, including National Institutes of Health controlled clinical trials in kidney transplantation.

Dr Jordan has written hundreds of articles in scientific journals and authored about two dozen book chapters. He was appointed by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to advise Congress on the safety and efficacy of intravenous gammaglobulin products. Dr. Jordan has been principal investigator on 3 NIH Controlled Clinical Trials in Kidney Transplantation. Dr. Jordan has received the Medical Sciences Award from the UCLA Alumni Association, Gift of Life Award from the National Kidney Foundation, Established Investigator Award from the American Society of Transplantation and Distinguished Alumni Award from the University of North Carolina-Chapel Hill School of Medicine. Dr. Jordan is a member of national and international professional societies and has served on the editorial boards of numerous professional journals.

Dr. Robert A. Montgomery
Dr. Robert A. Montgomery, MD, DPhil, FACS is the Chief of the Division of Transplantation, Professor of Surgery, and the Director Comprehensive Transplant Center at Johns Hopkins, Baltimore, Maryland. Dr. Robert A. Montgomery is the inaugural recipient of the Margery K. and Thomas Pozefsky Endowed Professorship in Kidney Transplantation.

Dr. Montgomery was part of the team that developed the laparoscopic procedure for live kidney donation, a procedure that has become the standard throughout the world.

Dr. Montgomery is considered a world expert on kidney transplantation for highly sensitized and ABO incompatible patients. Dr. Montgomery has received important awards and distinctions including a Fulbright Scholarship, a Thomas J. Watson Fellowship and memberships in the Phi Beta Kappa and Alpha Omega Alpha academic honor societies. He has been awarded multiple scholarships from The American College of Surgeons and The American Society of Transplant Surgeons. The National Kidney Foundation of Maryland has recognized his contributions to the field of transplantation with the Champion of Hope Award and the National Kidney Registry recognized him with the Terasaki Medical Innovation Award.

Professor Kathryn Wood
Kathryn Wood is Professor of Immunology in the Nuffield Department of Surgical Sciences, University of Oxford, where she runs the Transplantation Research Immunology Group. Her research focuses on tolerance induction at the molecular and cellular level, immune regulation and interactions between the immune system and stem cell derived tissues.    She is a Fellow of The Academy of Medical Sciences and received a Royal Society Wolfson Merit Award for research excellence.  Professor Wood’s research achievements have also been recognized internationally, including receiving a Gold Medal awarded by The Catalan Society of Transplantation (2011), The Rose Payne Award from the American Society of Histocompatibility and Immunogenetics (2011), Excellence in Transplantation Science Award from The Transplantation Society (2012) and the Maharshi Sushruta Award (2012).  Professor Wood's professional activities include a broad array of responsibilities both nationally and internationally.  She was President of The Transplantation Society (2004-2006), leads the Women in Transplantation initiative, and is an editor of "Transplantation". 

About IdeS
IdeS, a unique molecule with a novel mechanism, is a bacterial enzyme that cleaves human IgG antibodies. IdeS degrades all IgG specifically, swiftly and efficiently. IdeS has been tested for safety and efficacy in numerous in vitro and in vivo models. During 2013, a Phase I clinical trial on 29 healthy subjects was conducted, demonstrating IdeS as efficacious and well tolerated with a favorable safety profile. During 2014 and 2015, a Phase II clinical trial in sensitized patients awaiting kidney transplantation has been conducted. Preliminary data shows that IdeS has very good efficacy in highly sensitized patients on the kidney transplant waitlist. The study shows that IdeS has the capacity to make sensitized patients eligible for transplantation by decreasing HLA antibodies to levels acceptable for transplantation. In addition to transplantation, IdeS has potential indications within a variety of rare autoimmune diseases. IdeS is protected by several patents and has been published in numerous peer review journals.

The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on May 6, 2015 at 08:00 CET.

For further information, please contact:
Hansa Medical AB
Göran Arvidson, CEO and CFO
Mobile: 46 706-33 30 42
E-mail: goran.arvidson@hansamedical.com

Christian Kjellman, Ph.D

Chief Scientific Officer
Mobile: +46 705 717417

E-mail: christian.kjellman@hansamedical.com

www.hansamedical.com

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser. 

Tags:

About Us

Hansa Medical is a biopharmaceutical company focused on novel immunomodulatory enzymes. Lead project IdeS is an antibody-degrading enzyme in clinical development, with potential use in transplantation and rare autoimmune diseases. Other projects include HBP (a market introduced diagnostic marker for severe sepsis) and EndoS (an antibody-modulating bacterial enzyme in pre-clinical development). The company is based in Lund, Sweden. Hansa Medical's share (HMED) is listed on Nasdaq First North in Stockholm with Remium Nordic AB as Certified Adviser.